For example, pre-treatment profiling of T cell subtypes such as CD8+/Treg ratios or expression of activation/exhaustion markers (PD-1, TIM-3, granzyme B) or T cell clonal diversity in the primary tumor, may help identify patients more likely to benefit from checkpoint blockade or adoptive cell therapies. Here, CD8A is linked to neoplasm.